Aura Biosciences, Inc.
NASDAQ:AURABiotechnology
-$0.09 today
- Market cap
- $743.09M
- Beta
- 0.39
- P/E (TTM)
- -3.7
- EPS (TTM)
- -$1.67
Volume 0.69M
Average 0.52M
AURA Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Aura Biosciences, Inc.NASDAQ: AURA
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses growth accelerates
Q1 FY2026 operating expenses of $34.59M rose 19.1% year over year, ahead of the +15.1% change in trailing-twelve-month operating expenses. Sequentially, it rose 27.0% from the prior quarter. Over 3 fiscal years it compounded at +23.2% a year.
Context
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +19.1% holds above the trailing-twelve-month pace of +15.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 112.79M USD
- Year-over-year change
- +17.3%
- 4-year CAGR
- +33.7%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 112.79M | +17.3% |
| FY2024 | 2024-12-31 | 96.12M | +14.8% |
| FY2023 | 2023-12-31 | 83.7M | +38.8% |
| FY2022 | 2022-12-31 | 60.3M | +71.0% |
| FY2021 | 2021-12-31 | 35.25M | — |
Operating Expenses vs competitors
How AURA compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +15.1% is the 7th highest of 11, against a peer median of +43.1%.
- Over three fiscal years its annual growth of +23.2% compares with a peer median of +34.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $299.94M USD | +54.6% | +80.8% | — | |
| LTM Mar 2026 | $287.65M USD | +34.6% | +27.1% | 3777.4% | |
| LTM Mar 2026 | $234.87M USD | +104.1% | +34.7% | 369.9% | |
| LTM Mar 2026 | $173.51M USD | -10.6% | -12.1% | 110.5% | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $122.7M USD | +143.6% | +40.1% | — |
| LTM Mar 2026 | $118.05M USD | +15.1% | +23.2% | — | |
| LTM Mar 2026 | $89.69M USD | +109.1% | +36.8% | — | |
| FY2025 | $81.18M USD | +51.6% | +60.1% | 1249.5% | |
| LTM Mar 2026 | $70.72M USD | +14.9% | -10.8% | 1583.9% | |
| LTM Mar 2026 | CHF 69.81M CHF | -10.3% | +34.7% | 13851.6% | |
| LTM Mar 2026 | $59.37M USD | -22.3% | +2.5% | 17821.9% | |
| Peer median (excluding AURA) | — | +43.1% | +34.7% | 1583.9% | |
Competitors are the stored peer set for AURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 1.3M | 0 | 0 |
| Gross Profit | 0 | 0 | (1.3M) | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 25.16M | 42.24M | 63.94M | 73.3M | 90.3M |
| Selling, General & Admin | 10.09M | 18.06M | 19.76M | 22.81M | 22.49M |
| Operating Expenses | 35.25M | 60.3M | 83.7M | 96.12M | 112.79M |
| Depreciation & Amortization | 831K | 1.18M | 1.3M | 1.22M | 1.13M |
| EBITDA | (34.41M) | (57.59M) | (74.98M) | (85.58M) | (104.95M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (35.25M) | (60.3M) | (84.99M) | (96.12M) | (112.79M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 13K | 1.86M | 8.59M | 9.43M | 6.63M |
| Interest Expense | 13K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (1K) | 1.53M | 8.72M | 9.31M | 6.71M |
| Income Before Tax | (35.25M) | (58.76M) | (76.27M) | (86.81M) | (106.08M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 137K | 112K | 108K |
| Net Income | (35.25M) | (58.76M) | (76.41M) | (86.92M) | (106.19M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.58) | (1.96) | (1.93) | (1.75) | (1.76) |
| EPS (Diluted) | (1.58) | (1.96) | (1.93) | (1.75) | (1.76) |
| Weighted Avg Shares | 29.21M | 29.94M | 39.62M | 49.65M | 60.34M |
| Weighted Avg Shares (Diluted) | 29.21M | 29.94M | 39.62M | 49.65M | 60.34M |
Aura Biosciences, Inc.
NASDAQ:AURA
Intrinsic Alpha fair value
Locked
Current Price
$7.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.